Feeling the pressure.

Quote






And how many reps do we really need selling Ingrezza with just 1 indication now?
I have spoken with several in my area that say Austedo is gaining ground and if I'm not mistaking, they have fewer reps and their data for TS is supposed to be really good. Plus they are doing really well in Neurology with HD indication.
 






50% increase in sales reps was not the right call. Should’ve been a staggered ramp up in areas where reps were needed most. Now we will have additional pressure and higher sales goals/percentage growth to pay for the additional head count. Expect to see this additional cost eating into bonus comp payouts.
 












anonymous said:
50% increase in sales reps was not the right call. Should’ve been a staggered ramp up in areas where reps were needed most. Now we will have additional pressure and higher sales goals/percentage growth to pay for the additional head count. Expect to see this additional cost eating into bonus comp payouts.
Click to expand...

Hang in there. We'll have 2 more drugs in our bag in only a few years
 






I honestly thought Austedo would be an easy drug to outsell. Austedo is doing well in my territory. Seems like docs will switch quickly because of the somnolence too. Anybody else have these issues? No need to mock me "learn how to sell" etc., Ive been doing this 15 years.
 






anonymous said:
I honestly thought Austedo would be an easy drug to outsell. Austedo is doing well in my territory. Seems like docs will switch quickly because of the somnolence too. Anybody else have these issues? No need to mock me "learn how to sell" etc., Ive been doing this 15 years.
Click to expand...
Im out pacing them 3 to 1 ez, in a very mediocre performing territory. Bid, Bid, Bid!
Depression and Suicidality, in this pt population, r u kidding. Remember, only Vat mat 2, u remember the rest. Seriously say it on every call. They barely deserve the scraps they are getting.
Good selling!
 






One indication, failed studies, 2 dosing strengths, high somnolence, dual 2D6-3A4 pathway metabolism ...coming after you.

BID, ohh, as if these patients aren't already taking BID and TID meds. Keep selling the high depression stuff, you're just looking like an idiot when they find out you're giving half-truths. That's only in the HD population...you know, the indication you don't have along with the failed Tourette's study.
 






My customers have no issue with the added benefit of somnolence, sleep is welcomed in much of this population. Who's the idiot now? Furthermore, personally, my geography is filling Ing 122 to 12 Aus for the quarter. Thus, I have no reason to waste time and energy selling against or talking poorly about your product.
 






anonymous said:
One indication, failed studies, 2 dosing strengths, high somnolence, dual 2D6-3A4 pathway metabolism ...coming after you.

BID, ohh, as if these patients aren't already taking BID and TID meds. Keep selling the high depression stuff, you're just looking like an idiot when they find out you're giving half-truths. That's only in the HD population...you know, the indication you don't have along with the failed Tourette's study.
Click to expand...
 






anonymous said:
One indication, failed studies, 2 dosing strengths, high somnolence, dual 2D6-3A4 pathway metabolism ...coming after you.

BID, ohh, as if these patients aren't already taking BID and TID meds. Keep selling the high depression stuff, you're just looking like an idiot when they find out you're giving half-truths. That's only in the HD population...you know, the indication you don't have along with the failed Tourette's study.
Click to expand...


I have never once looked at the Austedo board on cafepharma. Austedo is so insignificant in my territory. The only time I discuss it, is on a rare chance a customer asks a direct question about it. So whomever the Austedo rep is on here commenting, go away and get back to work. You have a VERY long way to go if you’re “coming after” us.
As a side note - this may be the longest amount of time I have ever spent discussing your product.
 






Glad you think you're untouchable in your territory. You should look at national numbers, Austedo is coming after you...then when the Tourette's indication comes (you know, the one of many other studies your drug failed) it'll really be go time.

Good luck waiting out your five years for all those stock options.
 






anonymous said:
Im out pacing them 3 to 1 ez, in a very mediocre performing territory. Bid, Bid, Bid!
Depression and Suicidality, in this pt population, r u kidding. Remember, only Vat mat 2, u remember the rest. Seriously say it on every call. They barely deserve the scraps they are getting.
Good selling!
Click to expand...

You guys keep lying to your docs about the suicidality and depression with Austedo. I get the question all the time and am happy to show the data and make you out the liar that you know you are. The TD indication does not have a black box warning and we prove it each and every time we are asked. The HD indication has it because the label is from another drug. You people are clueless and we make sure we let the docs know that you guys are lying and misinforming them because you want them to keep writing your products. They all know you are lying about it. Please keep saying it. The docs are telling us what you say and they tell our upper management as well. Won't be long before you guys get slapped down over it.
 












anonymous said:
50% increase in sales reps was not the right call. Should’ve been a staggered ramp up in areas where reps were needed most. Now we will have additional pressure and higher sales goals/percentage growth to pay for the additional head count. Expect to see this additional cost eating into bonus comp payouts.
Click to expand...

So, how did that prediction turn out?
 
























Top Bottom
Back
Quote